Hideko Yamauchi1, Chizuko Nakagawa2, Hiroyuki Takei3, Calvin Chao4, Carl Yoshizawa4, Hiroshi Yagata2, Atsushi Yoshida2, Naoki Hayashi2, Susanne Hell5, Seigo Nakamura6. 1. St Luke's International Hospital, Department of Breast Surgery, Tokyo, Japan. Electronic address: hideyama@luke.or.jp. 2. St Luke's International Hospital, Department of Breast Surgery, Tokyo, Japan. 3. Saitama Cancer Center, Division of Breast Surgery, Saitama, Japan. 4. Genomic Health, Inc, Redwood City, CA. 5. Medical Affairs Consulting, Speyer, Germany. 6. St Luke's International Hospital, Department of Breast Surgery, Tokyo, Japan; Department of Breast Surgery, Showa University, Tokyo, Japan.
Abstract
BACKGROUND: In this study we investigated if the 21-gene assay result affects adjuvant decision-making in Japanese women with ER+ invasive EBC. PATIENTS AND METHODS: A total of 124 consecutive eligible patients with ER+, HER2-negative EBC and 0 to 3 positive lymph nodes were enrolled. Treatment recommendations, physicians' confidence and patients' decisional conflict before and after knowledge of the Recurrence Score results of the 21-gene assay were recorded. RESULTS: One-hundred four patients (84%) had N0 disease, including micrometastases, and 20 (16%) had N+ disease. Overall, recommendations changed in 33% (95% CI, 24%-43%) of N0 and 65% (95% CI, 41%-85%) of N+ patients. In 27 of 48 (56%) of N0 and 13 of 15 (87%) of N+ patients an initial recommendation for chemohormonal therapy was revised to only hormonal therapy after assay results, and in 7 of 56 (13%) of N0 and 0 of 5 N+ patients from only hormonal to combined chemohormonal therapy. Decisions appeared to follow the Recurrence Score results for low and high values. For patients with intermediate Recurrence Score values, overall recommendations for chemohormonal treatment tended to decrease after assay results. Physicians' confidence increased in 106 of 124 (85.5%; 95% CI, 78%-91%) cases. Patients' decisional conflict significantly improved as indicated by changes in the total score and the 5 defined subscores (P = .014 for Informed Subscore; P < .001 for all others). CONCLUSION: Results from this prospective study in a Japanese population confirm an effect of the 21-gene assay results on adjuvant treatment decision-making, consistent with reported experiences from the United States and Europe.
BACKGROUND: In this study we investigated if the 21-gene assay result affects adjuvant decision-making in Japanese women with ER+ invasive EBC. PATIENTS AND METHODS: A total of 124 consecutive eligible patients with ER+, HER2-negative EBC and 0 to 3 positive lymph nodes were enrolled. Treatment recommendations, physicians' confidence and patients' decisional conflict before and after knowledge of the Recurrence Score results of the 21-gene assay were recorded. RESULTS: One-hundred four patients (84%) had N0 disease, including micrometastases, and 20 (16%) had N+ disease. Overall, recommendations changed in 33% (95% CI, 24%-43%) of N0 and 65% (95% CI, 41%-85%) of N+ patients. In 27 of 48 (56%) of N0 and 13 of 15 (87%) of N+ patients an initial recommendation for chemohormonal therapy was revised to only hormonal therapy after assay results, and in 7 of 56 (13%) of N0 and 0 of 5 N+ patients from only hormonal to combined chemohormonal therapy. Decisions appeared to follow the Recurrence Score results for low and high values. For patients with intermediate Recurrence Score values, overall recommendations for chemohormonal treatment tended to decrease after assay results. Physicians' confidence increased in 106 of 124 (85.5%; 95% CI, 78%-91%) cases. Patients' decisional conflict significantly improved as indicated by changes in the total score and the 5 defined subscores (P = .014 for Informed Subscore; P < .001 for all others). CONCLUSION: Results from this prospective study in a Japanese population confirm an effect of the 21-gene assay results on adjuvant treatment decision-making, consistent with reported experiences from the United States and Europe.
Authors: K Willemsma; W Yip; N LeVasseur; K Dobosz; C Illmann; S Baxter; C Lohrisch; C E Simmons Journal: Curr Oncol Date: 2020-05-01 Impact factor: 3.677
Authors: Joseph Gligorov; Xavier B Pivot; William Jacot; Hervé L Naman; Dominique Spaeth; Jean-Louis Misset; Rémy Largillier; Jean-Loup Sautiere; Anne de Roquancourt; Christophe Pomel; Philippe Rouanet; Roman Rouzier; Frederique M Penault-Llorca Journal: Oncologist Date: 2015-06-25
Authors: Anna Kuchel; Tim Robinson; Charles Comins; Mike Shere; Mohini Varughese; Geoff Sparrow; Ajay Sahu; Louise Saunders; Amit Bahl; Simon J Cawthorn; Jeremy P Braybrooke Journal: Br J Cancer Date: 2016-03-08 Impact factor: 7.640